diabetes

Abacus Health Solutions publishes diabetes management article in American Journal of Managed Care

Abacus Health Solutions publishes diabetes management article in American Journal of Managed Care

CRANSTON, R.I. — Abacus Health Solutions (Abacus), a pioneer in chronic health condition management, announces the publication of a new applied research article titled “Behavior-Based Diabetes Management:  Impact on Care, Hospitalizations, and Costs” in the American Journal of Managed Care, March 2021 edition. The study examines the impact of the Abacus Diabetes Care Rewards Program, a care

PQA Endorses Two New Diabetes-Focused Health Plan Performance Measures

PQA Endorses Two New Diabetes-Focused Health Plan Performance Measures

ALEXANDRIA, Va. – The Pharmacy Quality Alliance (PQA), through a majority vote of its members, has endorsed two new health plan performance measures. The measures evaluate medications to treat individuals with diabetes. More than 34 million Americans have diabetes, according to the Centers for Disease Control and Prevention. These measures will help evaluate the quality of

GlucoDown expanding to 2000 Walmart pharmacies for 2021

GlucoDown expanding to 2000 Walmart pharmacies for 2021

BENTONVILLE, Ark.— Soon it will be much easier and more convenient to buy GlucoDown at Walmart. Beginning this month, in-store availability of GlucoDown Diabetic Friendly Peach Tea Mix is expanding to more than 2000 Walmart pharmacies for 2021 – more GlucoDown at more Walmart pharmacies nationwide than ever before. Walmart has stocked GlucoDown Diabetic Friendly Peach

Mylan and Biocon Biologics announce launch of Semglee for diabetes care

Mylan and Biocon Biologics announce launch of Semglee for diabetes care

 PITTSBURGH—  Mylan N.V.  and Biocon Biologics India Ltd., a subsidiary of Biocon Ltd., announced on Monday the U.S. launch of Semglee (insulin glargine injection) in vial and pre-filled pen presentations, approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is not

National health care leaders collaborate with PQA on diabetes project

National health care leaders collaborate with PQA on diabetes project

ALEXANDRIA, Va. – Humana, Pfizer  and Walgreens are collaborating with the Pharmacy Quality Alliance (PQA) to evaluate the impact of pharmacist-provided care on medication use, health and economic outcomes in patients with diabetes. The project brings together national leaders in pharmacy, care delivery, medications, and health plan administration to demonstrate the value of collaboration between

Noninvasive exams can help head off liver disease

Noninvasive exams can help head off liver disease

A race is under way among pharmaceutical companies to develop drugs that treat a spectrum of liver diseases, including nonalcoholic fatty liver disease (NAFLD), an asymptomatic condition characterized by elevated levels of fat in the liver, and its more severe form, nonalcoholic steatohepatitis (NASH). The main risk factors for fatty liver disease include a sedentary

A shortfall in diabetes diagnosis and care for 14 years

A shortfall in diabetes diagnosis and care for 14 years

Adults with diabetes have a two- to three-times increased risk of early death compared to individuals without diabetes. Leaving diabetes uncontrolled can damage the kidneys, eyes, nerves and heart. Our new study published in JAMA Internal Medicine found that less than one in four American adults diagnosed with diabetes reach the care targets recommended by

Pharmacists’ Life-Changing Role in Diabetes

Pharmacy accounts for the vast majority of chain drug store sales, and diabetes care is among the larger contributors to pharmacy volume. But the category is not without challenges. Most recently, insulin price inflation has raised a barrier to the purchase of — and adherence to — this life-saving prescription. The issue led Democratic and

Noninvasive technologies help battle diabetes and NAFLD

Noninvasive technologies help battle diabetes and NAFLD

The American Liver Foundation estimates that over 30% of the U.S. population has some degree of nonalcoholic fatty liver disease (NAFLD), the most common type of liver disease in the Western world. This can impact other facets of their overall health, because NAFLD has been linked to diabetes, obesity, insulin resistance and other metabolic risk

NACDS hails pharmacists’ role in diabetes management and prevention

NACDS hails pharmacists’ role in diabetes management and prevention

ARLINGTON, Va. – A National Association of Chain Drug Stores ) op-ed published by Morning Consult today describes the role of community pharmacy practice and of NACDS members’ philanthropic initiatives in helping to prevent and manage diabetes. “Two of the central areas where pharmacies and pharmacists have the greatest impact in diabetes are medication management and behavior change

Lilly presents new diabetes data at ADA session

Lilly presents new diabetes data at ADA session

ORLANDO, Fla. — Eli Lilly’s ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from three phase 1b studies evaluating URLi compared to Humalog. URLi is Lilly’s novel mealtime insulin currently in phase 3 development. The data was presented in

Study to probe Jardiance effects on kidney disease

Study to probe Jardiance effects on kidney disease

RIDGEFIELD, Conn. and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly and Co.  yesterday announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance on the progression of kidney disease and the occurrence of cardiovascular death, in adults with established chronic kidney disease with and without diabetes. EMPA-KIDNEY will be independently conducted, analyzed and reported by the Medical